Abstract 361P
Background
HR+/HER2- breast cancer are less sensitive to neoadjuvant chemotherapy (NCT), with a low objective response rate (ORR) of approximately 65% and a much lower pathological complete response (pCR) rate ranging from 5% to 10%. This phase 2 study aims to evaluate the efficacy and safety of adding fulvestrant to NCT in patients (pts) with HR+/HER2- breast cancer, and to investigate the predictive value of 18F-FES PET/CT for effectiveness.
Methods
In this single-arm phase 2 study, eligible pts were female with histologically confirmed HR+/HER2- locally advanced breast cancer (IIB-IIIC). Pts received fulvestrant (500 mg, on days 0, 14, 28, then every 28 days thereafter, every 4 weeks for six cycles) plus AC-T regimen, followed by surgery. Premenopausal women received a concomitant GnRH analogue. Pts underwent 18F-FES PET/CT examination at baseline. The primary endpoint was ORR. Secondary endpoints include tpCR (ypT0/is ypN0), overall survival (OS), and safety.
Results
From Dec 2020 to Sep 2022, 36 pts were enrolled. The median age was 53 years (range, 35-67), 78% were ECOG PS 1, 69% were postmenopausal, 92% were nodal involved, and 83% had stage III. After neoadjuvant therapy, the ORR and DCR were 86.1% (95% CI, 70.5%-95.3%) and 100% (95% CI, 90.3%-100.0%), respectively. All pts completed surgery, with a tpCR rate 8.3% (3/36; 95% CI, 1.8%-22.5%). 29 (80.6%; 95% CI, 64.0%-91.8%) pts had pathological tumor response [Miller-Payne (MP) grade ≥3]. Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 22% (8/36). The most common TEAEs were neutropenia (13.9%) and leukopenia (8.3%). Among the 36 pts, 24 completed 18F-FES PET/CT scan at baseline. The average SUVmax in primary breast lesions was 4.17 (range 1.00-12.80). The SUVmax was significantly associated with MP grade (R=0.82, p=8.4e-07). The SUVmax of the primary tumor from pts with MP grade 2/3 was significantly lower than those in pts with MP grade 4/5 (p=2.33e-05).
Conclusions
The addition of fulvestrant to NCT showed manageable toxicity and promising antitumor activity for pts with HR+/HER2- locally advanced breast cancer. The SUVmax of 18F-FES PET/CT was positively correlated with patient efficacy.
Clinical trial identification
ChiCTR2000041235.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. L.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
338P - Breast cancer follow-up: A population-based cohort study
Presenter: Serena Di Cosimo
Session: Poster session 03
339P - An online mindfulness-based stress-reduction (MBSR) intervention for breast cancer (BC) survivors: A randomized trial
Presenter: Misael Salazar-Alejo
Session: Poster session 03
340P - Novel application of spatial analyses to investigate environmental factors and hormone receptor-positive breast cancer
Presenter: Alexandra Thomas
Session: Poster session 03
341P - Impact of environmental temperature on clinical outcomes of early-stage breast cancer (BC)
Presenter: Arya Mariam Roy
Session: Poster session 03
342P - Fertility preservation in young breast cancer patients: Patient's knowledge and perception
Presenter: Zeineb Naimi
Session: Poster session 03
343P - Modulation of the immune system (ImS) during moderate physical activity (mPA) in breast cancer (BC) patients (pts) treated with neoadjuvant chemotherapy (NACT)
Presenter: Ornella Garrone
Session: Poster session 03
344P - Epidemiological analysis and overall survival of female breast cancer in a developing middle eastern country over 18 years
Presenter: Mahmoud Abunasser
Session: Poster session 03
345P - The effect of early post-operative exercise on shoulder function in breast cancer patients: A randomised controlled trial
Presenter: Jihee Min
Session: Poster session 03
348P - Long-term opioid use following treatment of localized breast cancer: A real-world analysis
Presenter: Ayelet Shai
Session: Poster session 03